{"name":"Sebela Women's Health Inc.","slug":"sebela-womens-health-inc","ticker":"","exchange":"","domain":"sebelawomenshealth.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"LevoCept","genericName":"LevoCept","slug":"levocept","indication":"Vasomotor symptoms associated with menopause","status":"phase_3"},{"name":"VeraCept","genericName":"VeraCept","slug":"veracept","indication":"Congenital adrenal hyperplasia","status":"phase_3"}]}],"pipeline":[{"name":"LevoCept","genericName":"LevoCept","slug":"levocept","phase":"phase_3","mechanism":"LevoCept is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling to treat menopausal symptoms and related conditions in women.","indications":["Vasomotor symptoms associated with menopause","Menopausal bone health and osteoporosis prevention"],"catalyst":""},{"name":"VeraCept","genericName":"VeraCept","slug":"veracept","phase":"phase_3","mechanism":"VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).","indications":["Congenital adrenal hyperplasia","Cushing's syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":11,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}